Voted one of New York Magazine's Best Doctors, 2008, Pediatric Hematology/Oncology
In 1981, the Platelet Disorders Center did the first studies of intravenous gammaglobulin in the treatment of ITP. This was followed by studies with IV anti-D (Winrho) beginning in 1987 and many other studies of the pathophysiology and treatment of ITP.
More than one hundred publications on ITP in children and adults have followed, including four first and second authored articles in the New England Journal of Medicine.
In 2003, Dr. Bussel was selected as on of 15 representatives of the American Society of Hematology (SPARKII) to meet with representatives of the NIH to plan research directions in the future.
Adults have worse ITP than do children. Therefore, trials and studies at the center have increasingly included them with the first publication on the treatment of adults in 1983. The center is the country's and the world's leader in clinical trials of refractory ITP in exploring novel agents including those that modulate the immune system.
Another area of Dr. Bussel's special expertise is the treatment of fetuses affected by alloimmune thrombocytopenia. This is a platelet incompatibility between the parents that affects the fetus. Treatment can be given during the pregnancy to the mother to increase the platelet count in the fetus, prevent hemorrhage, and allow for a healthy baby to be born whose thrombocytopenia will usually disappear within weeks.
(212) 746-3400 
(212) 746-8609
Back to Top